Compare Remitly Global Inc (RELY) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Remitly Global Inc vs Twist Bioscience Corp — how do they compare? Remitly Global Inc trades at $23.6 (market cap $4.98B), while Twist Bioscience Corp trades at $160.84 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 2× Remitly Global Inc's market cap, and Twist Bioscience Corp is more actively traded (4,229,037 versus 3,501,150). Which is the better fit depends on your goals — on Pluang, investors hold Remitly Global Inc for 53 Days and Twist Bioscience Corp for 27 Days on average.
| RELY | TWST | |
|---|---|---|
Market Cap | $4.98B | $10.08B |
Volume | 3,501,150 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $26.92 | $205.00 |
52-Week Low | $12.20 | $25.45 |
Typical Hold Time | 53 Days | 27 Days |
Enterprise Value | $4.34B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELY trades at $22.93, down 1.16% on the day, with a bullish technical signal from moving averages. The company shows strong fundamental momentum, with Q2 2026 revenue growth of 20% to $495 million and three consecutive quarterly EPS beats. Analyst consensus is strongly bullish with a $30.50 price target, supported by expanding profit margins and active customer growth exceeding 10 million.
Outlook remains positive given robust revenue growth and profitability expansion, but risks include competitive pressures in fintech and reliance on continued customer acquisition. The stock offers upside to analyst targets, though volatility may persist amid market shifts.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
